Advaxis Reports First Quarter Ended January 31, 2022 Financial Results and Provides a Business Update
March 17, 2022 09:00 ET
|
Advaxis, Inc.
Presented Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones Priced Offering of $5 Million Convertible Redeemable Preferred Stock through a Private...
Advaxis Reports Fiscal Year 2021 Financial Results and Provides a Business Update
February 14, 2022 16:35 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
Advaxis Prices Offering of $5,000,000 of Convertible Redeemable Preferred Stock Through a Private Placement
January 28, 2022 08:00 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
Advaxis Presents Updated Clinical Data from Ongoing Phase 1/2 Trial of ADXS-503 in NSCLC and Upcoming Milestones
January 11, 2022 08:00 ET
|
Advaxis, Inc.
Updated data show a second partial response in Part B Overall response rate of 15.4% and disease control rate of 46% in Part B with durable clinical benefit in patients with prior disease...
Advaxis Announces Acceptance for Trading on the OTCQX
December 22, 2021 16:05 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (OTCQX: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...
Advaxis to Continue to Explore Additional Options to Maximize Stockholder Value
December 17, 2021 08:00 ET
|
Advaxis, Inc.
Stockholders approved Proposal 1 in support of Biosight merger Proposal 2 reverse stock split, a condition for completing the merger of Advaxis and Biosight, was not approved MONMOUTH...
Advaxis Issues Letter to Stockholders Regarding Recent Special Meeting Results
December 09, 2021 08:00 ET
|
Advaxis, Inc.
Stockholders passed Proposals 1 (the Merger) and 4 (Executive Compensation) Advaxis urges stockholders to vote “FOR” Proposal 2 at the upcoming special meeting in order to best position the...
Advaxis Issues Letter and Second Video Message to Stockholders Regarding Upcoming Special Meeting
November 24, 2021 08:00 ET
|
Advaxis, Inc.
Company releases video message highlighting the need for all proposals to pass in order to consummate the proposed Biosight transaction Advaxis urges stockholders to vote “FOR” all of the proposals...
Nasdaq Grants Advaxis, Inc. an Extension to December 20, 2021, to Complete Merger Transaction with Biosight, Ltd. and Satisfy Initial Listing Requirements
November 22, 2021 08:00 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS) (“Advaxis” or the “Company”), a clinical-stage biotechnology company focused on the development and...
Advaxis, Inc. Issues Letter to Stockholders
November 19, 2021 08:00 ET
|
Advaxis, Inc.
MONMOUTH JUNCTION, N.J., Nov. 19, 2021 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy...